GlaxoSmithKline PLC Director/PDMR Shareholding (4344F)
July 12 2019 - 10:55AM
UK Regulatory
TIDMGSK
RNS Number : 4344F
GlaxoSmithKline PLC
12 July 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Ms E Walmsley
=== ======================== ============================================
b) Position/status Chief Executive Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 19
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr R G Connor
=== ======================== ============================================
b) Position/status President, Global Vaccines
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 62
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr N Hirons
=== ======================== ============================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 12
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mrs S Jackson
=== ======================== ============================================
b) Position/status SVP, Global Communications and CEO Office
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 57
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr D Jackson
=== ======================== ================================================
b) Position/status PCA of Mrs S Jackson (SVP, Global Communications
and CEO Office)
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 19
----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2019-07-11
=== ======================== ================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr L Miels
=== ======================== ============================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 3
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr D S Redfern
=== ======================== ============================================
b) Position/status Chief Strategy Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 70
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr R Simard
=== ======================== ============================================
b) Position/status President, Pharmaceuticals Supply Chain
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 19
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr P C Thomson
=== ======================== ============================================
b) Position/status President, Global Affairs
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 40
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mrs V A Whyte
=== ======================== ============================================
b) Position/status Company Secretary
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 July 2019, on shares
held through the Company's Share Reward
Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP16.5060 51
----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2019-07-11
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHZLLFFKDFEBBF
(END) Dow Jones Newswires
July 12, 2019 10:55 ET (14:55 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024